Lucy Bailey

Shield Therapeutics

Having joined Shield Therapeutics as a secondee in 2015, Lucy Bailey has been at the heart of the transformation the company has gone through since then. Following its AIM IPO that year, the company proceeded to commercialise its iron deficiency pill Feraccru throughout Europe. In 2018, Bailey was made general counsel and company secretary just as the company moved strategy from self- commercialising to looking for a licensing partner.

Since Shield signed an exclusive licence agreement with Norgine for it to commercialise the iron deficiency pill in Europe, Australia and New Zealand, Bailey has become an expert in licensing law. Shortly after that, she set out to get FDA approval for the drug in the US, achieved in July 2019, which means Shield can now seek a license partner, and in China.

Last year, Shield also achieved a positive result on a clinical drug trial conducted over 56 sites, a two-year project on which Bailey managed the key legal aspects, moving a key drug product manufacturing agreement from the UK to France and also managing two pieces of patent litigation.